Informations sur le produit
TC-S 7003 is a small-molecule drug that has been orally administered in clinical trials for the treatment of inflammatory diseases. TC-S 7003 has been shown to inhibit the activation of kinase signaling pathways, which are involved in cancer and hematopoietic cell proliferation. TC-S 7003 binds to collagen and inhibits the degradation of collagen by inhibiting matrix metalloproteinases (MMPs), which cause inflammation. TC-S 7003 also prevents the mitochondrial membrane potential from decreasing, as this will lead to an increase in reactive oxygen species (ROS) production and cell death.